Unexpectedly, we recently found that ICT with the anti-mouse CTLA-4 monoclonal antibody (mAb) 9D9 increases the proportion of TA-HEVs in mouse preclinical tumor models.11 The gene discussed is CTLA4; the disease is neoplasm.